Kura Oncology, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined cancers. The filing covers the three months ended March 31, 2023, with comparative results for the three months ended March 31, 2022. The company had 131 full-time employees and 68.4 million common shares outstanding as of March 31, 2023.
- Ziftomenib: Phase 2 registration-directed development in NPM1-mutant acute myeloid leukemia (AML); combination studies were planned for 2023.
- Tipifarnib: Phase 1/2 KURRENT-HN study with Novartis in biomarker-defined head and neck cancer; enrollment in the HRAS-overexpression cohort was discontinued and the PIK3CA cohort was prioritized.
- KO-2806: FDA-cleared IND, with a first-in-human Phase 1 study expected to begin in the second half of 2023.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Product revenue | None | None | No approved products or product sales |
| Research and development expense | $25.2 million | $20.9 million | +$4.3 million |
| General and administrative expense | $11.4 million | $11.9 million | -$0.5 million |
| Total operating expenses | $36.6 million | $32.8 million | +$3.8 million |
| Other income, net | $2.5 million | $0.3 million | +$2.2 million |
| Net loss | $34.1 million | $32.5 million | +$1.6 million loss |
| Net loss per share | $0.50 | $0.49 | Higher loss per share |
| Net cash used in operating activities | $35.9 million | $32.2 million | +$3.7 million use |
- Cash, cash equivalents and short-term investments totaled $405.9 million at March 31, 2023, compared with $438.0 million at December 31, 2022. Cash and cash equivalents alone were $27.1 million; short-term investments were $378.8 million.
- Management expects existing cash, cash equivalents and short-term investments to fund operations into the fourth quarter of 2025, based on current plans.
- Investing activities generated $11.1 million of cash, primarily from marketable-security maturities exceeding purchases. Financing activities provided no cash during the quarter.
- The company had a $10.0 million term loan outstanding, included in long-term debt, with a facility permitting up to $125.0 million of total borrowings subject to conditions. The loan matures in November 2027 and bears variable interest subject to an 8.65% floor.
- Total stockholders’ equity was $395.2 million at March 31, 2023, versus $420.3 million at December 31, 2022; accumulated deficit was $602.9 million.
- Share-based compensation expense was $6.8 million, compared with $6.7 million in Q1 2022.
Material changes versus the prior comparable period
- Research and development expense increased 20%, primarily from higher ziftomenib clinical costs and increased KO-2806 preparation costs. Tipifarnib costs declined following closure of further enrollment in its registration-directed trial.
- Interest and other income increased substantially to $2.9 million from $0.3 million as a result of higher investment income.
- Operating cash use increased 11% to $35.9 million, reflecting the higher net loss and investment-related non-cash accretion effects.
- Net loss increased 5% despite higher interest income, as operating expenses grew faster than other income.
- The company recognized a $2.8 million employee retention credit as a reduction of personnel costs and recorded a corresponding receivable, with cash expected in the second half of 2023.
- Unrealized losses on available-for-sale securities declined to $6.0 million from $8.1 million at year-end 2022, primarily reflecting interest-rate movements rather than credit deterioration.
Guidance, outlook, risks and unusual items
- Management expects R&D expenses to increase as clinical development of ziftomenib, tipifarnib and KO-2806 continues.
- The first patient in the KOMET-007 ziftomenib combination study was expected in the first half of 2023; KOMET-008 was expected to begin dosing in the second half of 2023.
- The company expects to determine the optimal biologically active dose for the PIK3CA cohort of KURRENT-HN in mid-2023.
- KOMET-001 data included a reported 30% complete remission rate among 600 mg NPM1-mutant AML patients in the Phase 1b cohort as of the January 31, 2023 cutoff. Differentiation syndrome remained a key safety risk, particularly in KMT2A-rearranged AML.
- Kura has no approved products, no product revenue and expects continuing losses and negative operating cash flow. Substantial additional financing will likely be required.
- Potential funding sources include equity offerings, debt, collaborations and licensing transactions. The company had not used its $150.0 million ATM facility as of the filing.
- Key risks include clinical-trial failure or delays, adverse events, patient-enrollment challenges, regulatory non-approval, reliance on third-party manufacturers and CROs, companion-diagnostic development, intellectual-property disputes, healthcare-pricing changes and dilution from future financing.
- The term-loan facility includes restrictive covenants, a minimum cash covenant and collateral over substantially all company assets other than intellectual property. Defaults could accelerate repayment obligations.
- The company disclosed exposure to financial-institution liquidity risk following 2023 bank failures and maintains deposits above standard FDIC insurance limits at a small number of institutions.
- Management concluded that disclosure controls and procedures were effective as of March 31, 2023, with no material changes in internal control over financial reporting.
Most important facts for investors to verify
- Whether ziftomenib’s Phase 2 NPM1-mutant AML study meets enrollment, safety and efficacy milestones and supports an accelerated or other regulatory pathway.
- Updated differentiation-syndrome rates, remission durability and overall benefit-risk results for ziftomenib.
- Progress and data from the KOMET-007 and KOMET-008 combination studies and the KO-2806 FIT-001 Phase 1 study.
- Whether the company’s projected cash runway to Q4 2025 remains valid as trial spending increases.
- Availability and terms of additional term-loan tranches, compliance with loan covenants and the effect of variable interest rates.
- Receipt and collectability of the $2.8 million employee retention credit.
- Potential dilution from the ATM facility, equity awards, warrants and any future financing.
- Regulatory and commercial requirements for companion diagnostics, manufacturing capacity and third-party collaboration support.